帕罗西汀治疗抑郁症疗效和药物不良反应的双盲对照研究

A RANDOMIZED DOUBLE-BLIND AMITRIPTYLINE-CONTROLLED STUDY OF PAROXETINE TREATMENT FOR MAJOR DEPRESSION

为观察帕罗西汀治疗抑郁症的疗效和药物不良反应，采用随机、双盲、对照设计，对９０例符合ＤＳＭ－Ⅲ－Ｒ抑郁症诊断标准，Ｈａｍｉｌｔｏｎ抑郁量表（ＨＡＭＤ）（２１项版本）≥１８分的患者，分别予帕罗西汀和阿密替林治疗６周。ＨＡＭＤ，Ｈａｍｉｌｔｏｎ焦虑量表（ＨＡＭＡ），临床疗效总评量表（ＣＧＩ），治疗时出现的症状量表（ＴＥＳＳ）评分和临床疗效评定显示，帕罗西汀抗抑郁疗效肯定，其起效时间，抗抑郁症状谱，总体疗效与阿密替林相当。其药物不良反应程度及发生率，尤其对心血管、神经、植物神经系统的副反应明显低于阿密替林。本研究结果提示，帕罗西汀是一疗效肯定，不良反应轻微的抗抑郁剂。

To investigate the anti-depressive efficacy and side effects of parocxetine, a selective serotonin reuptake inhibitor(SSRIs), and compared it with amitriptyline, a randomized, double- blind and controlled study was conducted. Ninety patients who met DSM-Ⅲ-R criteria for major depression and HAMD(21-item version) score≥18 were treated with Paroxetine( 44 cases) or amitriptyline(46 cases) for 6 weeks.HAMD, HAMA, CGI and TESS were used to measure the anti-depressive efficacy and side effects. The results showed paroxetine was similar to amitriptyline in its start time of action, antidepressive spectrum,and clinical global efficacy and with much less and milder side effects than amitriptyline, especially on autonomous nervous system, nervous system and cardiovascular system. The results of this study indicates paroxetine is a effective antidepressant with mild side effects when compared with amitriptyline which is a typical tricyclic antidepressant.